FrancophonIA/ELRC3.0 huggingface dataset:
English: What measures are being taken to ensure the safe and effective use of Imatinib Actavis?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Imatinib Actavis?
English: Because Imatinib Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je lijek Imatinib Actavis generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imatinib Actavis have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Imatinib Actavis nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Imatinib Actavis has been shown to have comparable quality and to be bioequivalent to Glivec.
Croatian: Europska agencija za lijekove zaključila je kako je, u skladu sa zahtjevima EU-a, utvrđeno da lijek Imatinib Actavis posjeduje usporedivu kakvoću te da je bioekvivalentan s lijekom Glivec.
English: Imatinib Actavis is used to treat adults with DFSP that cannot be removed with surgery, and in adults who cannot have surgery when the cancer has returned after treatment or has spread to other parts of the body.
Croatian: Lijek Imatinib Actavis primjenjuje se u liječenju odraslih bolesnika s DFSP-om koji se ne može kirurški odstraniti i odraslih bolesnika koji ne mogu ići na kirurški zahvat kada se rak vrati nakon prethodnog liječenja ili se proširio na druge dijelove tijela.
English: What are the benefits and risks of Imatinib Actavis?
Croatian: Koje su koristi i rizici od lijeka Imatinib Actavis?
English: An overview of Imatinib Actavis and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Imatinib Actavis i zašto je odobren u EU-u
English: For more information about using Imatinib Actavis, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Imatinib Actavis pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Imatinib Actavis is used with other cancer medicines in adults and children who have been newly diagnosed with Ph+ ALL.
Croatian: Imatinib Actavis primjenjuje se s drugim lijekovima protiv raka u odraslih i djece u kojih je tek dijagnosticiran Ph+ ALL.
English: • dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Croatian: • dermatofibrosarkoma protuberans (DFSP), vrste raka (sarkoma) kod kojeg se stanice u tkivu ispod kože nekontrolirano dijele.
English: What is Imatinib Actavis and what is it used for?
Croatian: Što je Imatinib Actavis i za što se primjenjuje?
English: As for every medicine, the company provided studies on the quality of Imatinib Actavis.
Croatian: Kao i za svaki lijek, tvrtka je dostavila podatke o ispitivanjima kakvoće lijeka Imatinib Actavis.
English: Why is Imatinib Actavis authorised in the EU?
Croatian: Zašto je Imatinib Actavis odobren u EU-u?
English: Imatinib Actavis is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα;
Croatian: Imatinib Actavis primjenjuje se za liječenje odraslih bolesnika s HES-om ili KEL-om sa specifičnom preraspodjelom dvaju gena naziva FIP1L1 i PDGFRα;
English: Imatinib Actavis received a marketing authorisation valid throughout the EU for Imatinib Actavis on 17 April 2013.
Croatian: Lijek Imatinib Actavis dobio je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji od 17. travnja 2013.
English: As for all medicines, data on the use of Imatinib Actavis are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Imatinib Actavis kontinuirano se prate.
English: Other information about Imatinib Actavis
Croatian: Ostale informacije o lijeku Imatinib Actavis
English: The active substance in Imatinib Actavis, imatinib, is a protein-tyrosine-kinase inhibitor.
Croatian: Djelatna tvar lijeka Imatinib Actavis je imatinib, inhibitor protein-tirozin kinaze.
English: Imatinib Actavis is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
Croatian: Imatinib Actavis koristi se za liječenje odraslih bolesnika s MD/MPD-om s preraspodjelom gena za receptor faktora rasta koji potječe od trombocita (PDGFR);
English: It is also used in children in the ‘chronic phase' of the disease if it is not responding to interferon alfa (another medicine used to treat cancer), and in more advanced phases of the disease (‘accelerated phase' and ‘blast crisis').
Croatian: Lijek se također primjenjuje u djece u „kroničnoj fazi” bolesti nakon neuspjeha terapije interferonom-alfa (drugim lijekom za liječenje raka) te u uznapredovalim fazama bolesti („u ubrzanoj fazi” ili „u blastičnoj krizi”); Imatinib Actavis također se primjenjuje u odraslih s Ph+ CML-om u blastičnoj krizi.
English: Imatinib Actavis is a ‘generic medicine'.
Croatian: Actavis je „generički lijek”.
English: Imatinib Actavis is used when the patients are ‘Philadelphia-chromosome positive' (Ph+).
Croatian: Lijek Imatinib Actavis primjenjuje se u liječenju bolesnika „pozitivnih na Philadelphia kromosom” (Ph+).
English: Therefore, the Agency's view was that, as for Glivec, the benefit of Imatinib Actavis outweighs the identified risk and it can be authorised for use in the EU.
Croatian: Stoga je stav Agencije da koristi od lijeka Imatinib Actavis, kao i od lijeka Glivec, nadmašuje identificirani rizik te da lijek može biti odobren za primjenu u EU-u.
English: Imatinib Actavis is a cancer medicine that contains the active substance imatinib.
Croatian: Actavis je lijek protiv raka koji sadrži djelatnu tvar imatinib.
English: • chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control.
Croatian: • kronične mijeloične leukemije (CML), raka bijelih krvnih stanica kod kojega granulociti (vrsta bijelih krvnih stanica) počinju nekontrolirano rasti.
English: The medicine is used in children who have been newly diagnosed with Ph+ CML and who cannot have a bone marrow transplant.
Croatian: Lijek Imatinib Actavis primjenjuje se u djece s novodijagnosticiranim Ph+ CML-om u koje nije moguća transplantacija koštane srži.
English: How has Imatinib Actavis been studied?
Croatian: Kako je Imatinib Actavis ispitivan?
English: How is Imatinib Actavis used?
Croatian: Kako se Imatinib Actavis koristi?
English: How does Imatinib Actavis work?
Croatian: Kako djeluje Imatinib Actavis?
English: Component of a multipack, cannot be sold separately.
Croatian: Sadržaj višestrukog pakiranja ne može se prodavati odvojeno.
English: No data are available in older children (see sections 4.8 and 5.1)
Croatian: Nema dostupnih podataka za stariju djecu (vidjeti dijelove 4.8 i 5.1)
English: What Hexyon is and what it is used for
Croatian: Što je Hexyon i za što se koristi
English: An updated RMP should be submitted:
Croatian: Ažuriran RMP treba dostaviti:
English: Other medicines or vaccines and Hexyon
Croatian: Drugi lijekovi ili cjepiva i Hexyon
English: No significant clinical interaction with other treatments or biological products has been reported except in the case of immunosuppressive therapy (see section 4.4).
Croatian: Nije prijavljena značajna klinička interakcija s drugim lijekovima ili biološkim proizvodima, osim u slučaju imunosupresivne terapije (vidjeti dio 4.4.).
English: If you forget one dose of Hexyon
Croatian: Ako ste zaboravili jednu dozu cjepiva Hexyon
English: Very rare (<1/10,000) Not known (cannot be estimated from available data)
Croatian: Nepoznato (ne može se procijeniti iz dostupnih podataka)
English: • As with any vaccine, Hexyon may not protect 100% of children who receive the vaccine.
Croatian: • Kao i druga cjepiva, Hexyon možda neće zaštititi 100% djece koja prime cjepivo.
English: At the end of this period, Hexyon should be used or discarded.
Croatian: Na kraju tog razdoblja Hexyon se mora upotrijebiti ili zbrinuti.
English: To make sure that Hexyon is suitable for your child, it is important to talk to your doctor or nurse if any of the points below apply to your child.
Croatian: Kako biste bili sigurni da je cjepivo Hexyon prikladno za Vaše dijete, važno je da obavijestite svog liječnika ili medicinsku sestru ako se neke od dolje navedenih točaka odnose na Vaše dijete.
English: Possible side effects Like all medicines, this vaccine can cause side effects, although not everybody gets them.
Croatian: Moguće nuspojave Kao i svi lijekovi, ovo cjepivo može uzrokovati nuspojave iako se neće javiti kod svakoga.
English: What Hexyon looks like and contents of the pack
Croatian: Kako Hexyon izgleda i sadržaj pakiranja
English: Anaphylactic reaction*
Croatian: Anafilaktička reakcija*
English: Pack of 10 for multipack (without blue box)
Croatian: Pakiranje od 10 za višestruko pakiranje (bez plavog okivra)
English: Pack of 1, 10 or 50.
Croatian: Pakiranje od 1, 10 ili 50.
English: Serious allergic reactions are a rare possibility (may affect up to 1 in 1,000 people) after receiving this vaccine.
Croatian: Ozbiljne alergijske reakcije javljaju se rijetko (javlja se kod manje od 1 od 1000 osoba) nakon primanja ovog cjepiva.
English: In clinical studies in individuals who received Hexyon, the most frequently reported reactions include injection-site pain, irritability, crying, and injection-site erythema.
Croatian: U kliničkim ispitivanjima provedenima na pojedincima koji su cijepljeni cjepivom Hexyon, najčešće prijavljivane reakcije uključuju bol na mjestu injiciranja, razdražljivost, plač i eritem na mjestu injiciranja.
English: • Hexyon should not be mixed with other medicinal products.
Croatian: • Hexyon se ne smije miješati s drugim lijekovima.
English: 1541 avenue Marcel Mérieux 69280 Marcy L'Etoile France
Croatian: 1541, avenue Marcel Mérieux 69280 Marcy l'Etoile Francuska
English: • Hexyon must be administered intramuscularly.
Croatian: • Hexyon se mora primijeniti intramuskularno.
English: Other paediatric population:
Croatian: Ostala pedijatrijska populacija
English: Vaccination with Hexyon may need to be delayed until your child is better.
Croatian: U tom slučaju cijepljenje cjepivom Hexyon može se odgoditi do oporavka Vašeg djeteta.
English: The safety of Hexyon in children over 24 months of age has not been studied in clinical trials.
Croatian: Sigurnost cjepiva Hexyon u djece starije od 24 mjeseca nije ispitivana u kliničkim ispitivanjima.
English: Hexyon is a whitish, cloudy suspension.
Croatian: Hexyon je bjelkasta, mutna suspenzija.
English: The safety and efficacy of Hexyon in infants less than 6 weeks of age have not been established.
Croatian: Sigurnost i djelotvornost cjepiva Hexyon u dojenčadi koja ima manje od 6 tjedana nisu još ustanovljene.
English: Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000)
Croatian: Manje često (≥1/1 000 do <1/100) Rijetko (≥1/10 000 do <1/1 000) Vrlo rijetko (<1/10 000)
English: Hexyon will be given to your child by a doctor or nurse trained in the use of vaccines and who are equipped to deal with any uncommon severe allergic reaction to the injection (see section 4 Possible side effects).
Croatian: Cjepivo Hexyon će Vašem djetetu dati liječnik ili medicinska sestra koji su osposobljeni i pripremljeni za cijepljenje i postupanje u slučaju pojave bilo kakve neuobičajene ozbiljne alergijske reakcije na cijepljenje (vidjeti dio 4.“Moguće nuspojave“).
English: Hexyon (DTaP-IPV-HB-Hib) is a vaccine used to protect against infectious diseases.
Croatian: Hexyon je cjepivo (DTaP-IPV-HB-Hib) koje se koristi u svrhu zaštite od zaraznih bolesti.
English: However children with long standing problems with their immune system such as HIV infection (AIDS) may still be given Hexyon but the protection may not be as good as in children whose immune system is healthy.
Croatian: Ipak, djeca s dugotrajnim problemima s imunološkim sustavom kao što je HIV-infekcija (AIDS) mogu se cijepiti cjepivom Hexyon iako njih cjepivo neće štiti kao zdravu djecu.
English: Hexyon is given as an injection into a muscle (intramuscular route IM) in the upper part of your child's leg or upper arm.
Croatian: Hexyon se daje kao injekcija u mišić (intramuskularnim putem, i.m.) u gornji dio natkoljenice ili nadlaktice Vašeg djeteta.
English: Do not use Hexyon if your child:
Croatian: Vaše se dijete ne smije cijepiti cjepivom Hexyon ako:
English: d- Potential adverse events (i.e. adverse events which have been reported with other vaccines containing one or more of the components or constituents of Hexyon and not directly with Hexyon)
Croatian: d- Potencijalne nuspojave (tj. nuspojave koje su prijavljene za druga cjepiva koja sadrže jedan ili više sastavnih dijelova cjepiva Hexyon, a ne izravno za cjepivo Hexyon).
English: The administration of Hexyon must be carefully considered in individuals who have a history of serious or severe reactions within 48 hours following administration of a vaccine containing similar components.
Croatian: Primjena cjepiva Hexyon mora se pažljivo razmotriti kod osoba koje u anamnezi imaju ozbiljnu ili tešku reakciju unutar 48 sati od prethodnog cijepljenja cjepivom sa sličnim komponentama.
English: A history of febrile convulsions, a family history of convulsions or Sudden Infant Death Syndrome (SIDS) do not constitute a contraindication for the use of Hexyon.
Croatian: Febrilne konvulzije u anamnezi, obiteljska anamneza konvulzija ili sindrom iznenadne smrti dojenčeta (SIDS) nisu kontraindikacija za primjenu cjepiva Hexyon.
English: 1 pre-filled syringe (0.5 ml) without needle 10 pre-filled syringes (0.5 ml) without needle 50 pre-filled syringes (0.5 ml) without needle 1 pre-filled syringe (0.5 ml) with 1 needle 10 pre-filled syringes (0.5 ml) with 10 needles 1 pre-filled syringe (0.5 ml) with 2 needles 10 pre-filled syringes (0.5 ml) with 20 needles
Croatian: 1 napunjena štrcaljka (0,5 ml ) bez igle 10 napunjenih štrcaljki (0,5 ml) bez igle 50 napunjenih štrcaljki (0,5 ml) bez igle 1 napunjena štrcaljka (0,5 ml) s 1 iglom 10 napunjenih štrcaljki (0,5 ml) s 10 igala 1 napunjena štrcaljka (0,5 ml) s 2 igle 10 napunjenih štrcaljki (0,5 ml) s 20 igala
English: A dose of 0.5 ml is withdrawn using a syringe for injection.
Croatian: Dozu od 0,5 ml izvući pomoću štrcaljke za injekciju.
English: Months N=249** N=204† N=178†† N=177 to
Croatian: N=204† N=178†† N=177 do
English: When given at the same time with other vaccines, Hexyon will be given at different injection sites.
Croatian: Kada se daje istovremeno s drugim cjepivima, Hexyon će biti primijenjena na neko drugo mjesto aplikacije.
English: Τηλ.
Croatian: Hexyon.
English: OTHER Sanofi Pasteur Europe
Croatian: Sanofi Pasteur Europe
English: Studies on long-term persistence of vaccine induced antibodies following varying infant / toddler primary series and following Hepatitis B vaccine given at birth or not have shown maintenance of levels above the recognized protective levels or antibody thresholds for the vaccine antigens (see Table 3).
Croatian: Ispitivanja dugoročne trajnosti protutijela induciranih cjepivom nakon različitih primarnih serija cijepljenja dojenčadi/male djece i nakon što je cjepivo protiv hepatitisa B bilo ili nije bilo primjenjeno po rođenju, pokazala su održavanje razina iznad utvrđenih zaštitnih razina ili graničnih vrijednosti protutijela za antigene iz cjepiva (vidjeti Tablicu 3.)
English: • Hexyon will only help to prevent these diseases if they are caused by the bacteria or viruses targeted by the vaccine.
Croatian: • Hexyon pomaže u zaštiti od navedenih bolesti samo ako su prouzročene bakterijama odnosno virusima protiv kojih je ovo cjepivo namijenjeno.
English: Hexyon in pre-filled syringes EU/1/13/829/002
Croatian: Hexyon u napunjenim štrcaljkama EU/1/13/829/002
English: Hexyon suspension for injection
Croatian: Hexyon suspenzija za injekciju
English: Hexyon must not be mixed with any other vaccines or other parenterally administered medicinal products.
Croatian: Hexyon se ne smije miješati s drugim cjepivima ili drugim lijekovima koji se primjenjuju parenteralno.
English: First course of vaccination (primary vaccination) Your child will receive either two injections given at an interval of two months or three injections given at an interval of one to two months (at least four weeks apart).
Croatian: Prva serija cijepljenja (primarno cijepljenje) Vaše dijete će primiti dvije injekcije u razmaku dva mjeseca ili tri injekcije u razmaku od jedan do dva mjeseca (razmak od najmanje četiri tjedna).
English: Table 3: Seroprotection ratesa at the age of 4.5 years old after vaccination with Hexyon Antibody Thresholds
Croatian: Tablica 3: Stope serozaštite u dobi od 4,5 godina nakon cijepljenja s cjepivom Hexyon
English: The immune responses to Hib (PRP) and pertussis antigens (PT and FHA) were evaluated after 2 doses in a subset of subjects receiving Hexyon (N=148) at 2, 4, 6 months of age.
Croatian: Imunološki odgovori na antigene Hib (PRP) i antigene hripavca (PT i FHA) procijenjeni su nakon primjene 2 doze u podskupini ispitanika koji su primili cjepivo Hexyon (N=148) u dobi od 2, 4, 6 mjeseci.
English: • Hexyon will not protect against hepatitis infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E.
Croatian: • Hexyon neće zaštititi od zaraze hepatitisom prouzročene drugim uzročnicima poput virusa hepatitisa A, hepatitisa C i hepatitisa E.
English: Diphtheria Toxoid not less than 20 IU2
Croatian: Toksoid difterije ne manje od 20 IU2
English: There may be a clinically relevant interference in the antibody response of Hexyon and a varicella vaccine and these vaccines should not be administered at the same time.
Croatian: Može doći do klinički značajne interferencije u odgovoru protutijela na cjepiva Hexyon i cjepivo protiv varičela te se ta cjepiva ne smiju primjenjivati istovremeno.
English: Vaccine efficacy of the acellular pertussis (aP) antigens contained in Hexyon against the most severe WHO-defined typical pertussis (≥ 21 days of paroxysmal cough) is documented in a randomised double-blind study among infants with a 3 dose primary series using a DTaP vaccine in a highly endemic country (Senegal).
Croatian: Djelotvornost cjepiva koje sadrži antigene nestaničnog hripavca (aP) koji su sadržani u cjepivu Hexyon protiv najtežeg tipičnog hripavca koji je opisala Svjetska zdravstvena organizacija (≥ 21 dana paroksizmalnog napadaja kašlja) dokumentirana je u randomiziranom, dvostruko slijepom ispitivanju provedenom među dojenčadi koja je primila 3 doze primarne serije uz primjenu DTaP cjepiva u zemlji s visokim stupnjem endemičnosti (Senegal).
English: How to store Hexyon
Croatian: Kako čuvati cjepivo Hexyon
English: The long term capability of the acellular pertussis (aP) antigens contained in Hexyon to reduce pertussis incidence and control pertussis disease in the childhood has been demonstrated in a 10-year national pertussis surveillance on pertussis disease in Sweden with the pentavalent DTaP-IPV/Hib vaccine using a 3, 5, 12 months schedule.
Croatian: Dugoročna sposobnost antigena nestaničnog hripavca (aP) sadržanih u cjepivu Hexyon u smanjivanju incidencije hripavca i u kontroli hripavca u djetinjstvu pokazana je u desetogodišnjem nacionalnom praćenju hripavca u Švedskoj s DTaP-IPV/Hib cjepivom u režimu primjene 3, 5, 12 mjeseci.
English: Hexyon in pre-filled syringes
Croatian: Hexyon u napunjenim štrcaljkama
English: Hexyon can be given at the same time as other vaccines such as pneumococcal vaccines, measlesmumps-rubella vaccines, rotavirus vaccines or meningococcal vaccines.
Croatian: Hexyon se može istovremeno primijeniti s drugim cjepivima, kao što su cjepiva protiv pneumokoka, cjepiva protiv ospica-zaušnjaka-rubeole, cjepiva protiv rotavirusa ili cjepiva protiv meningokoka.
English: Table 1: Seroprotection/Seroconversion rates* one month after a primary vaccination with 2 or 3 doses of Hexyon
Croatian: Tablica 1: Stope serozaštite/serokonverzije* mjesec dana nakon primarnog cijepljenja sa 2 ili 3 doze cjepiva Hexyon
English: Vaccination with Hexyon is contraindicated if the individual has experienced an encephalopathy of unknown aetiology, occurring within 7 days following prior vaccination with a pertussis containing vaccine (whole cell or acellular pertussis vaccines).
Croatian: Cijepljenje cjepivom Hexyon kontraindicirano je ako pojedinac ima encefalopatiju nepoznate etiologije, nastalu unutar 7 dana nakon prethodnog cijepljenja cjepivom koje sadrži komponentu hripavca (cjelostanična ili nestanična cjepiva protiv hripavca).
English: • sudden and serious malaise with drop in blood pressure causing dizziness and loss of consciousness, accelerated heart rate associated with respiratory disorders
Croatian: • nagla i ozbiljna malaksalost uz pad krvnog tlaka koji uzrokuje omaglicu i gubitak svijesti,
English: What you need to know before Hexyon is given to your child
Croatian: Što morate znati prije nego što Vaše dijete primi cjepivo Hexyon
English: Hexyon is available in pack containing 10 vials.
Croatian: Hexyon je dostupna u pakiranju koje sadrži 10 bočica.
English: Hexyon may be used as a booster in individuals who have previously been vaccinated with another hexavalent vaccine or a pentavalent DTaP-IPV/Hib vaccine associated with a monovalent hepatitis B vaccine.
Croatian: Hexyon se može primijeniti za docjepljivanje osoba koje su ranije bile cijepljenje nekim drugim šesterovalentnim cjepivom ili peterovalentnim DTaP-IPV/Hib cjepivom udruženim sa monovalentnim cjepivom protiv hepatitisa B.
English: Data on concomitant administration of Hexyon with a meningococcal C conjugate vaccine or a meningococcal group A, C, W-135 and Y conjugate vaccine have shown no clinically relevant interference in the antibody response to each of the antigens.
Croatian: Podaci o istovremenoj primjeni cjepiva Hexyon s konjugiranim cjepivom protiv meningokoka grupe C ili s konjugiranim cjepivom protiv meningokoka grupe A, C, W-135 i Y nisu pokazali klinički značajnu interferenciju u odgovoru protutijela na svaki od antigena.
English: History of an anaphylactic reaction after a previous administration of Hexyon.
Croatian: Anafilaktička reakcija nakon prijašnjeg cijepljenja cjepivom Hexyon.
English: Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).
Croatian: Hexyon (DTaP-IPV-HB-Hib) je indiciran za primarno cijepljenje i docjepljivanje dojenčadi i male djece od navršenih šest tjedana protiv difterije, tetanusa, hripavca, hepatitisa B, poliomijelitisa i invazivnih bolesti uzrokovanih bakterijom Haemophilus influenzae tip b (Hib).
English: Hexyon suspension for injection in pre-filled syringe Hexyon suspension for injection
Croatian: Hexyon suspenzija za injekciju u napunjenoj štrcaljki Hexyon suspenzija za injekciju
English: Multipack of 50 (5 packs of 10) pre-filled syringes without needle.
Croatian: Višestruko pakiranja od 50 (5 pakiranja s 10) napunjenih štrcaljki bez igle.
English: Multipack of 50 (5x10) (including blue box)
Croatian: Višestruko pakiranje od 50 (5x10)
English: Hexyon can be considered for the booster.
Croatian: Hexyon se može koristiti za docjepljivanje.
English: Prior to administration, the vial should be shaken in order to obtain a homogeneous, whitish, cloudy suspension.
Croatian: Prije primjene bočicu treba protresti kako bi se dobila homogena, bjelkasta, mutna suspenzija.
English: Where a dose of hepatitis B vaccine is given at birth, Hexyon can be used for supplementary doses of hepatitis B vaccine from the age of six weeks.
Croatian: Kada je po rođenju dobivena doza cjepiva protiv hepatitisa B, Hexyon se može primijeniti kao dodatna doza cjepiva protiv hepatitisa B počevši od starosne dobi od šest tjedana.